Form4insider filings, from the source

SEC Form 4 · accession 0001140361-17-038098

OncoMed Pharmaceuticals Inc · OMED

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
John A. Lewicki
Officer — EVP, Research & Development
Period of report
Oct 7, 2017
Accepted (ET)
Oct 10, 2017 · 7:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Oct 7, 2017A25,000$0.00A71,660D
Common StockF3holding———88,951ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F4$4.36Oct 7, 2017A50,000A—Oct 6, 2027Common Stock50,00050,000D

Explanation of responses